<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.dmsjournal.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Diabetology &amp; Metabolic Syndrome - Latest Articles</title>
        <link>http://www.dmsjournal.com</link>
        <description>The latest research articles published by Diabetology &amp; Metabolic Syndrome</description>
        <dc:date>2012-02-03T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/4/1/4" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/4/1/3" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/4/1/2" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/4/1/1" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/3/1/37" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/3/1/36" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/3/1/35" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/3/1/34" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/3/1/33" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/3/1/32" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.dmsjournal.com/content/4/1/4">
        <title>Salivary pH as a Marker of Plasma Adiponectin Concentrations in Women</title>
        <description>Background:
Plasma adiponectin is a significant correlate of the pro-inflammatory cardiometabolic risk profile associated with obesity and type 2 diabetes. Salivary pH is influenced by several cardiometabolic risk components such as inflammation, oxidation and numerous oral and systemic health modulators, including the menopausal status. This study aimed to assess the association between plasma adiponectin concentrations and salivary pH in women according to the menopausal status.MethodUnstimulated saliva collection was performed in 151 Caucasian women of French-Canadian origin (53 premenopausal women (PMW) and 98 menopausal women (MW)). Student&apos;s t test, ANOVA and linear regression models were used to assess the association between plasma adiponectin concentrations and salivary pH.
Results:
Plasma adiponectin levels increased as a function of salivary pH in the whole sample and among MW (r=0.29 and r=0.36, p&lt;0.001). The proportion of the variance of plasma adiponectin levels explained by the salivary pH (R2) was 10.8% (p&lt;0.001). Plasma adiponectin levels progressively increased across salivary pH quartiles (p=0.005).
Conclusions:
These results suggest that salivary pH is a significant correlate of plasma adiponectin levels in women. With the increasing prevalence of type 2 diabetes and obesity, new technologies should be developed to more easily monitor health status, disease onset and progression. Salivary pH, a simple, inexpensive and non-invasive measure, could be a very promising avenue.</description>
        <link>http://www.dmsjournal.com/content/4/1/4</link>
                <dc:creator>Monique Tremblay</dc:creator>
                <dc:creator>Yacine Loucif</dc:creator>
                <dc:creator>Julie Methot</dc:creator>
                <dc:creator>Diane Brisson</dc:creator>
                <dc:creator>Daniel Gaudet</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2012, null:4</dc:source>
        <dc:date>2012-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-4-4</dc:identifier>
                                <prism:require>/content/figures/1758-5996-4-4-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/4/1/3">
        <title>The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus</title>
        <description>Background:
Hyperuricemia is associated with obesity. The visceral adiposity and subcutaneous adiposity may be associated with the differential metabolic risk, and the distribution of abdominal adipose tissue was significantly altered in people with type 2 diabetes mellitus (DM) compared to healthy people. Our study was performed to determine to the association between the regional abdominal adipose tissue distribution and serum uric acid levels in people with type 2 DM.
Methods:
A total of 699 people with type 2 DM and who had undergone abdominal computed tomography assessment of the visceral fat area and subcutaneous fat area were included. The serum uric acid levels were measured by the uricase method. Hyperuricemia was defined by cut-off value of &gt; 7 mg/dl for men and &gt; 6 mg/dl for women.
Results:
The visceral fat area was positively associated with the serum uric acid levels after adjustment for age, sex, systolic blood pressure, diastolic blood pressure, serum creatinine, hemoglobin, serum albumin, serum high-density lipoprotein, serum triglyceride and hemoglobin A1c (beta-coefficient = 0.117, p &lt; 0.001). The logistic regression analysis showed that the visceral fat area was the significant independent predictor of hyperuricemia (OR 2.33, 95% CI, 1.21-4.50, p = 0.012). But there was no significant association between the subcutaneous fat area and the serum uric acid levels (beta-coefficient = 0.061, p = 0.255).
Conclusions:
our data shows that the visceral fat area was positively associated with the serum uric acid levels, but the subcutaneous fat area was not in people with type 2 DM.</description>
        <link>http://www.dmsjournal.com/content/4/1/3</link>
                <dc:creator>Tae Ho Kim</dc:creator>
                <dc:creator>Seong Su Lee</dc:creator>
                <dc:creator>Ji Han Yoo</dc:creator>
                <dc:creator>Sung Rae Kim</dc:creator>
                <dc:creator>Soon Jib Yoo</dc:creator>
                <dc:creator>Ho Cheol Song</dc:creator>
                <dc:creator>Yong-Soo Kim</dc:creator>
                <dc:creator>Euy Jin Choi</dc:creator>
                <dc:creator>Yong Kyun Kim</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2012, null:3</dc:source>
        <dc:date>2012-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-4-3</dc:identifier>
                                <prism:require>/content/figures/1758-5996-4-3-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/4/1/2">
        <title>Autonomic cerebral vascular response to sildenafil in  diabetic patient 

</title>
        <description>Background:
Erectile dysfunction is a common problem in type 2 diabetic patients who are at higher risk of cerebrovascular events, and it&apos;s recorded with sildenafil, a drug which is primarily used for erectile dysfunction. Objectives: We tested the hypothesis whether or not sildenafil modulates cerebrovascular reactivity (CVR) in patients with type 2 diabetes mellitus.
Methods:
A total of 35 male participants were enrolled; eighteen with type 2 diabetes mellitus matched with seventeen normal individuals. Transcranial Doppler Ultrasonographic examination (TCD) was performed for all participants to insonate the middle cerebral artery (MCA) through a trans-temporal window.  CVR was assessed by using breath holding (BH)-hyperventilation (HV) test, before and after oral 50mg sildenafil; recordings were analyzed by using SPSS program version 12.  Results: In normal individuals, sildenafil did not result in statistically significant change in breath holding index (BHI) from 0.91+/-0.11 to 0.81+/-0.09 and full range of vasodilatation (FVD) from (59.4%+/- 6.3%) to (53.7%+/- 4.9%).  In diabetic patients, giving sildenafil resulted in significant increase in BHI (from 0.74+/-0.14 to 1.03+/-0.14) and FVD (from 60.2%+/-4.96% to 74%+/- 4.8%), (p&lt;0.05). Conclusion: Sildenafil significantly improves CVR in type 2 diabetic patients but not in normal subjects.</description>
        <link>http://www.dmsjournal.com/content/4/1/2</link>
                <dc:creator>Fadhil Al-Amran</dc:creator>
                <dc:creator>Akeel Zwain</dc:creator>
                <dc:creator>Najah Hadi</dc:creator>
                <dc:creator>Ahmed Al-Mudhaffer</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2012, null:2</dc:source>
        <dc:date>2012-01-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-4-2</dc:identifier>
                                <prism:require>/content/figures/1758-5996-4-2-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-01-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/4/1/1">
        <title>Ten-week lifestyle changing program reduces several indicators for metabolic syndrome in overweight adults</title>
        <description>We aim to investigate the effectiveness of a 10-week lifestyle intervention focusing on physical activity and high fiber intake for reducing indicators for metabolic syndrome in overweight-obese individuals. A prospective study of 50 overweight (OW) adults (22 in the general educational group - G1; 28 in the high fiber nutrition group - G2) was performed.  Both groups were offered dietary counseling and supervised exercise. Clinical, anthropometric, dietary and plasma biochemical tests were performed at baseline - time 0 (T0) and after 10 weeks - time 1 (T1). Both groups improved their dietary quality, but only G2 presented higher intake of fruit and vegetables (servings/day), higher plasma beta-carotene levels and a 24% reduction of MetS incidence. Additionally G2 showed greater reductions in body fat (4%), and waist circumference (7%), obesity class III (2%) and obesity class II (14%) rate. Lifestyle intervention, including a high dietary fiber intake, improved healthy eating index and decreased body fat composition and plasma lipid concentrations leading to MetS incidence reduction.</description>
        <link>http://www.dmsjournal.com/content/4/1/1</link>
                <dc:creator>Marita Mecca</dc:creator>
                <dc:creator>Fernando Moreto</dc:creator>
                <dc:creator>Franz Burini</dc:creator>
                <dc:creator>Reinaldo Dalanesi</dc:creator>
                <dc:creator>Katia McLellan</dc:creator>
                <dc:creator>Roberto Burini</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2012, null:1</dc:source>
        <dc:date>2012-01-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-4-1</dc:identifier>
                                <prism:require>/content/figures/1758-5996-4-1-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-01-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/3/1/37">
        <title>High fat diet enhances cardiac abnormalities in SHR rats: Protective role of heme oxygenase-adiponectin axis
</title>
        <description>Background:
High dietary fat intake is a major risk factor for development of cardiovascular and metabolic dysfunction including obesity, cardiomyopathy and hypertension.
Methods:
The present study was designed to examine effect of high fat (HF) diet on cardio-vascular structure and function in spontaneously hypertensive rats (SHR), fed HF diet for 15 weeks, a phenotype designed to mimic metabolic syndrome.
Results:
Development of metabolic syndrome like phenotype was confirmed using parameters, including body weight, total cholesterol and blood pressure levels. High fat diet impaired vascular relaxation by acetylcholine and exacerbated cardiac dysfunction in SHRs as evidenced by lower left ventricular function, and higher coronary resistance (CR) as compared to controls (p &lt; 0.05). The histological examination revealed significant myocardial and peri-vascular fibrosis in hearts from SHRs on HF diet. This cardiac dysfunction was associated with increased levels of inflammatory cytokines, COX-2, NOX-2, TxB2 expression and increase in superoxide (O2
-) levels in SHR fed a HF diet (p &lt; 0.05). HO-1 induction via cobalt-protoporphyrin (CoPP,3 mg/kg), in HF fed rats, not only improved cardiac performance parameters, but also prevented myocardial and perivascular fibrosis. These effects of CoPP were accompanied by enhanced levels of cardiac adiponectin levels, pAMPK, peNOS and iNOS expression; otherwise significantly attenuated (p &lt; 0.05) in HF fed SHRs. Prevention of such beneficial effects of CoPP by the concurrent administration of the HO inhibitor stannic mesoporphyrin (SnMP) corroborates the role of HO system in mediating such effects.
Conclusion:
In conclusion, this novel study demonstrates that up-regulation of HO-1 improves cardiac and vascular dysfunction by blunting oxidative stress, COX-2 levels and increasing adiponectin levels in hypertensive rats on HF diet.</description>
        <link>http://www.dmsjournal.com/content/3/1/37</link>
                <dc:creator>Jian Cao</dc:creator>
                <dc:creator>Komal Sodhi</dc:creator>
                <dc:creator>Nitin Puri</dc:creator>
                <dc:creator>Sumit Monu</dc:creator>
                <dc:creator>Rita Rezzani</dc:creator>
                <dc:creator>Nader Abraham</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2011, null:37</dc:source>
        <dc:date>2011-12-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-3-37</dc:identifier>
                                <prism:require>/content/figures/1758-5996-3-37-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>37</prism:startingPage>
        <prism:publicationDate>2011-12-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/3/1/36">
        <title>Accuracy of a Novel Non-Invasive Technology Based EZSCAN System for the Diagnosis of Diabetes Mellitus in Chinese
</title>
        <description>Background:
A new simple technique based on iontophoresis technology (EZSCAN, Impeto Medical, Paris, France) has recently been developed for the screening of diabetes. In the present study, we investigated the accuracy of this system for the diagnosis of diabetes mellitus in Chinese.
Methods:
We performed the EZSCAN test in diabetic and non-diabetic subjects. EZSCAN measures electrochemical conductance (EC) at forehead, hands and feet, and derives a diabetes index with a value ranging from 0 to 100. Diabetes mellitus was defined as a plasma glucose concentration of at least 7 mmol/l at fasting or 11.1 mmol/l at 2 hours after glucose load, or as the use of antidiabetic drugs.
Results:
The 195 study participants (51% men, mean age 52 years) included 75 diabetic patients (use of antidiabetic drugs 81%) and 120 non-diabetic subjects. EC (micro Siemens, muSi) was significantly (P&lt;0.001) lower in diabetic patients at the hands (44 vs. 61) and feet (51 vs. 69) locations, but not at the forehead (15 vs. 17, P=0.39). When a diabetes index of 40 (suggested by the manufacturer) was used as the threshold, the sensitivity and specificity for the diagnosis of diabetes mellitus was 85% and 64%, respectively. In 80 patients who underwent an oral glucose tolerance test, EC at hands and feet and the diabetes index were significantly (P&lt;0.001) associated with both 2-hour post-load plasma glucose and serum glycosylated haemoglobin.
Conclusions:
EZSCAN might be useful in screening diabetes mellitus with reasonable sensitivity and specificity.</description>
        <link>http://www.dmsjournal.com/content/3/1/36</link>
                <dc:creator>Chang-Sheng Sheng</dc:creator>
                <dc:creator>Wei-Fang Zeng</dc:creator>
                <dc:creator>Qi-Fang Huang</dc:creator>
                <dc:creator>Jean-Paul Deslypere</dc:creator>
                <dc:creator>Yan Li</dc:creator>
                <dc:creator>Ji-Guang Wang</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2011, null:36</dc:source>
        <dc:date>2011-12-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-3-36</dc:identifier>
                                <prism:require>/content/figures/1758-5996-3-36-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2011-12-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/3/1/35">
        <title>Different exercise protocols improve metabolic syndrome markers, tissue triglycerides content and antioxidant status in rats.</title>
        <description>Background:
An increase in the prevalence of obesity entails great expenditure for governments. Physical exercise is a powerful tool in the combat against obesity and obesity-associated diseases. This study sought to determine the effect of three different exercise protocols on metabolic syndrome and lipid peroxidation markers and the activity of antioxidant enzymes in adult Wistar rats (120 days old).Methods: Animals were randomly divided into four groups: the control (C) group was kept sedentary throughout the study; the aerobic group (A) swam1 h per day, 5days per week, at 80% lactate threshold intensity; the strength group (S) performed strength training with four series of 10jumps, 5 days per week; and the Concurrent group (AS) was trained using the aerobic protocol three days per week and the strength protocol two days per week. Results Groups A and S exhibited a reduction in body weight compared to group C. All exercised animals showed a reduction in triglyceride concentrations in fatty tissues and the liver. Exercised animals also exhibited a reduction in lipid peroxidation markers (TBARS) and an increase in serum superoxide dismutase activity. Animals in group A had increased levels of liver catalase and superoxide dismutase activities. Conclusions We concluded that all physical activity protocols improved the antioxidant systems of the animals and decreased the storage of triglycerides in the investigated tissues.</description>
        <link>http://www.dmsjournal.com/content/3/1/35</link>
                <dc:creator>Jose Botezelli</dc:creator>
                <dc:creator>Lucieli Cambri</dc:creator>
                <dc:creator>Ana Ghezzi</dc:creator>
                <dc:creator>Rodrigo Dalia</dc:creator>
                <dc:creator>Pedro Scariot</dc:creator>
                <dc:creator>Carla Ribeiro</dc:creator>
                <dc:creator>Fabricio Voltarelli</dc:creator>
                <dc:creator>Maria Mello</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2011, null:35</dc:source>
        <dc:date>2011-12-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-3-35</dc:identifier>
                                <prism:require>/content/figures/1758-5996-3-35-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2011-12-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/3/1/34">
        <title>Nature of Fatty Acids in High Fat Diets Differentially Delineates Obesity-Linked Metabolic Syndrome Components in Male and Female C57BL/6J Mice.</title>
        <description>Background:
Adverse effects of high-fat diets (HFD) on metabolic homeostasis are linked to adipose tissue dysfunction. The goal of this study was to examine the effect of the HFD nature on adipose tissue activity, metabolic disturbances and glucose homeostasis alterations in male mice compared with female mice.
Methods:
C57BL/6J mice were fed either a chow diet or HFD including vegetal (VD) or animal (AD) fat. Body weight, plasmatic parameters and adipose tissue mRNA expression levels of key genes were evaluated after 20 weeks of HFD feeding.
Results:
HFD-fed mice were significantly heavier than control at the end of the protocol. Greater abdominal visceral fat accumulation was observed in mice fed with AD compared to those fed a chow diet or VD. Correlated with weight gain, leptin levels in systemic circulation were increased in HFD-fed mice in both sexes with a significant higher level in AD group compared to VD group. Circulating adiponectin levels as well as adipose tissue mRNA expression levels were significantly decreased in HFD-fed male mice. Although its plasma levels remained unchanged in females, adiponectin mRNA levels were significantly reduced in adipose tissue of both HFD-fed groups with a more marked decrease in AD group compared to VD group. Only HFD-fed male mice were diabetic with increased fasting glycaemia. On the other hand, insulin levels were only increased in AD-fed group in both sexes associated with increased resistin levels. VD did not induce any apparent metabolic alteration in females despite the increased weight gain. Peroxisome Proliferator-Activated Receptors gamma-2 (PPARgamma2) and estrogen receptor alpha (ERalpha) mRNA expression levels in adipose tissue were decreased up to 70% in HFD-fed mice but were more markedly reduced in male mice as compared with female mice.
Conclusions:
The nature of dietary fat determines the extent of metabolic alterations reflected in adipocytes through modifications in the pattern of adipokines secretion and modulation of key genes mRNA expression. Compared with males, female mice demonstrate higher capacity in controlling glucose homeostasis in response to 20 weeks HFD feeding. Our data suggest gender specific interactions between the diet&apos;s fatty acid source, the adipocyte-secreted proteins and metabolic disorders.</description>
        <link>http://www.dmsjournal.com/content/3/1/34</link>
                <dc:creator>Souhad El Akoum</dc:creator>
                <dc:creator>Vikie Lamontagne</dc:creator>
                <dc:creator>Isabelle Cloutier</dc:creator>
                <dc:creator>Jean-Francois Tanguay</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2011, null:34</dc:source>
        <dc:date>2011-12-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-3-34</dc:identifier>
                                <prism:require>/content/figures/1758-5996-3-34-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2011-12-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/3/1/33">
        <title>Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report.

</title>
        <description>IntroductionCircumscript, progressing lipoatrophy at the insulin injection sites is an unexplained, however rare condition in diabetes mellitus.Case presentationWe report a case of severe localised lipoatrophy developing during insulin pump-treatment (continuous subcutaneous insulin infusion) with the insulin analogue lispro (Humalog&#174;) in a woman with type-1 diabetes mellitus. After 11 months of progressing lipoatrophy at two spots on the abdomen, low-dose prednisone (5-10 mg) p.o. was given at breakfast for 8 months, whereby the atrophic lesions centripetally re-filled with subcutaneous fat tissue (confirmed by MRI) despite ongoing use of insulin lispro. However, 4 weeks after cessation of prednisone, lipoatrophy relapsed, but resolved after another 2 months of low-dose prednisone. No further relapse was noted during 12 months of follow-up on insulin-pump therapy with Humalog&#174;.
Conclusion:
Consistent with an assumed inflammatory nature of the condition, low-dose oral prednisone appeared to have cured the lipoatrophic reaction in our patient. Our observation suggests a temporary intolerance of the subcutaneous fat tissue to insulin lispro (Humalog&#174;), triggered by an unknown endogenous mechanism.</description>
        <link>http://www.dmsjournal.com/content/3/1/33</link>
                <dc:creator>Ernst Chantelau</dc:creator>
                <dc:creator>Ruth Praetor</dc:creator>
                <dc:creator>Jorg Praetor</dc:creator>
                <dc:creator>Ludger Poll</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2011, null:33</dc:source>
        <dc:date>2011-12-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-3-33</dc:identifier>
                                <prism:require>/content/figures/1758-5996-3-33-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>33</prism:startingPage>
        <prism:publicationDate>2011-12-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/3/1/32">
        <title>Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone</title>
        <description>Background:
FOXC2 has lately been implicated in diabetes and obesity as well as mitochondrial function and biogenesis and also as a regulator of mtTFA/Tfam. In this study, the expression of FOXC2 and selected genes involved in mitochondrial function and biogenesis in healthy subjects and in a matched cohort with type 2 diabetes patients before and after treatment with rosiglitazone was determined. Quantitative real time PCR was used to analyze both RNA and DNA from biopsies from subcutaneous adipose tissue.
Methods:
Blood samples and subcutaneous abdominal fat biopsies were collected from 12 T2D patients, of which 11 concluded the study, pre-treatment and 90 days after initiation of rosiglitazone treatment, and from 19 healthy control subjects on the first and only visit from healthy subjects. Clinical parameters were measured on the blood samples. RNA and DNA were prepared from the fat biopsies and gene expression was measured with real time PCR.
Results:
The expression level of genes in the mitochondrial respiratory complexes I - IV were significantly downregulated in the diabetic patients and restored in response to rosiglitazone treatment. Rosiglitazone treatment also increased the relative number of mitochondria in diabetic patients compared with controls. Furthermore, the transcription factors FOXC2 and mtTFA/Tfam displayed a response pattern identical to the mitochondrial genes.
Conclusions:
FOXC2, mtTFA/Tfam and subunits of the respiratory complexes I - IV show equivalent regulation in gene expression levels in response to TZD treatment. This, together with the knowledge that FOXC2 has a regulatory function of mtTFA/Tfam and mitochondrial biogenesis, suggests that FOXC2 has a possible functional role in the TZD activated mitochondrial response.</description>
        <link>http://www.dmsjournal.com/content/3/1/32</link>
                <dc:creator>Joakim Hakansson</dc:creator>
                <dc:creator>Bjorn Eliasson</dc:creator>
                <dc:creator>Ulf Smith</dc:creator>
                <dc:creator>Sven Enerback</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2011, null:32</dc:source>
        <dc:date>2011-11-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-3-32</dc:identifier>
                                <prism:require>/content/figures/1758-5996-3-32-toc.gif</prism:require>
                <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>32</prism:startingPage>
        <prism:publicationDate>2011-11-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

